Table 1.
Baseline characteristics of patients with locally advanced head and neck cancer (LAHNC) undergoing concurrent chemoradiotherapy (CCRT).
| Variables | Total |
|---|---|
| Numbers (%) or Mean SD | |
| Included number of patients | 98 (100) |
| Age (years) | 53.4 8.3 |
| Sex (female:male) | 3 (3.1):95 (96.9) |
| Smoking (no:yes) | 6 (6.1):92 (93.9) |
| Alcohol consumption (no:yes) | 22 (22.4):76 (77.6) |
| Betel nut consumption (no:yes) | 34 (34.7):64 (65.3) |
| CCI (0:1:2: ≥ 3) | 19 (19.4):27 (27.6):19 (19.4):33 (33.6) |
| Location | |
| Oral cavity | 50 (51.0) |
| Oropharynx | 22 (22.4) |
| Hypopharynx | 18 (18.4) |
| Larynx | 7 (7.1) |
| Unknown primary tumor | 1 (1.0) |
| Tumor status (T0:T1:T2:T3:T4) | 1 (1.0):4 (4.1):20 (20.4):10 (10.2):63 (64.3) |
| Lymph node status (N0:N1:N2:N3) | 17 (17.3):18 (18.4):57 (58.2):6 (6.1) |
| Tumor stage, AJCC 7th edition (III:IVA:IVB) | 9 (9.2):71 (72.4):18 (18.4) |
| Treatment modalities | |
| CCRT | 23 (23.5) |
| Surgery + CCRT | 49 (50.0) |
| Neoadjuvant chemotherapy + CCRT | 26 (26.5) |
| Cisplatin dose (mg/m2) | 221 57 |
| RT dose (Gy) | 67.1 4.9 |
| PG-SGA (well [0–3]:moderate [4–8):severe [≥9]) | 74 (75.5):23 (23.5):1 (1.0) |
| BMI (kg/m2) | 22.9 4.3 |
| Initial BWL (<10%: ≥ 10%) | 73 (73.5):26 (26.5) |
| 2-year RFSR | 57.1% |
Abbreviations: LAHNC, locally advanced head and neck cancer; CCRT, concurrent chemoradiotherapy; SD, standard deviation; CCI, Charlson Comorbidity Index; AJCC, American Joint Committee on Cancer; RT, radiotherapy; PG-SGA, patient-generated subjective global assessment; BMI, body mass index; BWL, body weight loss; RFSR, recurrence-free survival rate.